ArticleCurrent vascular pharmacology2024
Utilizing Pharmacogenomic Data for a Safer Use of Statins among the Emirati Population.
Article in Current vascular pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Pharmacogenomics in the United Arab Emirates: advances in population genomics and challenges in clinical implementation.Frontiers in pharmacology · 2026Review
- Ranking the Diabetes-related Safety Profile of Different Statin Drugs.Current pharmaceutical design · 2026Article
- Article
- Pharmacogenomic insights into atorvastatin and rosuvastatin adverse effects: a prospective observational study in the UAE's multiethnic population.Human genomics · 2025Observational
- Pharmacogenomic biomarkers of ACE inhibitor-induced cough in a multi-ethnic UAE cohort.Frontiers in pharmacology · 2025Article
- A multi-centre observational cohort study on pharmacogenomic predictors of rosuvastatin discontinuation in a multiethnic population.Frontiers in pharmacology · 2025Article
- Limitations and Future Directions for Research on Biomarkers and Endothelial Dysfunction in UAE Youth [Response to Letter].Diabetes, metabolic syndrome and obesity : targets and therapy · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundStatins are the most prescribed lipid-lowering drugs worldwide. The associated adverse events, especially muscle symptoms, have been frequently reported despite their perceived safety. Three pharmacogenes, the solute carrier organic anion transporter family member 1B1 (
objectivesThe present study aimed to examine variants in these pharmacogenes to predict the safety of statin use among the Emirati population.
methodsAnalyzing 242 whole exome sequencing data at the three genes enabled the determination of the frequencies of the single nucleotide polymorphisms (SNPs), annotating the haplotypes and the predicted functions of their proteins.
resultsIn our cohort, 29.8% and 5.4% had
conclusionAmong the sparse studies available, the present one demonstrates all
Indexed as
Identifiers
38284696What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.